Phaseline

Targets › TNF

TNF (Tumor necrosis factor): drug programs, companies and trials

27 programs from 26 companies in 125 trials: 58 Phase 2, 34 Phase 4, 18 Phase 1, 15 Phase 3; Immunology, Oncology, Genitourinary; next expected readout Nov 2026.

Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR, activating the tumor necrosis factor-mediated (TNF) signaling pathway. The TNF signaling pathway acts as a master regulator of the immune system, which either (1) promotes cell survival and inflammation by activating the canonical NF-kappa-B pathway or (2) trigger programmed cell death (apoptosis and necroptosis). (UniProt, P01375)

Open in Phaseline: the race on TNF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Taizhou Mabtech PharmaceuticalInfliximab
TNF-alpha inhibitor
TNFPhase 4Crohn Disease; Inflammatory Bowel Diseases; Ulcerative Colitis; Schizophrenia …Nov 2026
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
University of CalgaryCBD 100 mg OD
Interleukin-23 inhibitor
CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1Phase 4Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope …Dec 2026
Odense University HospitalCapsule FMT
Amiloride-sensitive sodium channel, ENaC blocker
GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1GPhase 4Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women …Dec 2026
Nanfang Hospital, Southern Medical UniversityEtanercept
TNF-alpha inhibitor
TNFPhase 4Spondyloarthritis (SpA)Mar 2027
Chia Tai Tianqing Pharmaceutical GroupAdalimumab
TNF-alpha inhibitor
TNFPhase 4Adult Non-infectious Uveitis; Crohn's Disease; Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease; Takayasu Arteritis …Feb 2028
Connecticut Children's Medical CenterAnti-TNF therapy (Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Huli
TNF inhibitor
TNFPhase 4Crohn DiseaseJul 2028
University Hospital, Strasbourg, FranceCertolizumab Pegol
TNF-alpha inhibitor
TNFPhase 4Rheumatoid ArthritisMar 2029
University Hospital, Strasbourg, Franceetanercept
TNF-alpha inhibitor
TNFPhase 4Rheumatoid ArthritisMar 2029
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sEtanercept
TNF-alpha inhibitor
TNFPhase 4Rheumatoid Arthritis–
Johnson & Johnson (Janssen)Golimumab
TNF-alpha inhibitor
TNFPhase 3Colitis, Ulcerative; Rheumatoid Arthritis; Peripheral SpondyloarthritisFeb 2027
PhilogenL19TNF
L19-targeting TNF fusion protein
TNFPhase 3Malignant Melanoma; Glioblastoma; Melanoma Stage III; Locally Advanced Basal Cell Carcinoma …Jul 2028
Assistance Publique - Hôpitaux de ParisCertolizumab Pegol
TNF-alpha inhibitor
TNFPhase 3Recurrent Unexplained Implantation FailureApr 2029
mAbxience ResearchMB04
TNF-alpha inhibitor
TNFPhase 3Rheumatoid Arthritis (RA)–
Wayne State UniversityEtanercept
TNF-alpha inhibitor
TNFPhase 2Tinnitus, Noise InducedDec 2026
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyPirfenidone
Anti-fibrotic agent with anti-inflammatory properties
TNF, TGF-BETAPhase 2To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal CarcinomaDec 2026
Sun Yat-sen UniversityrmhTNF-NC
Recombinant human tumor necrosis factor
TNFPhase 2Malignant AscitesDec 2026
Teva Branded Pharmaceutical Products R&DTEV-48574
TNF-α antagonist monoclonal antibody (duvakitug)
TNFPhase 2Crohn DiseaseJan 2027
Sir Run Run Shaw HospitalIcaritin
Downregulates TNF-α, IL-6, and PD-L1 expression; reduces MDSC proportion to modulate tumor
TNF, IL6, PDCD1LG1Phase 2Advanced Pancreatic Ductal AdenocarcinomaApr 2027
David Ware BranchCertolizumab Pegol
TNF-alpha inhibitor
TNFPhase 2High Risk PregnancyDec 2027
Chiesi FarmaceuticiCHF10067 (Zampilimab)
TNF-α inhibitor monoclonal antibody
TNFPhase 2Idiopathic Pulmonary FibrosisJun 2028
National Institute of Geriatrics, Rheumatology and Rehabilitation, PolandEtanercept
TNF-alpha inhibitor
TNFPhase 2SAPHO SyndromeOct 2028
Memorial Sloan Kettering Cancer CenterCertolizumab Pegol
TNF-alpha inhibitor
TNFPhase 2Lung Cancer–
Prestige BiopharmaAdalimumab (PBP1502)
TNF-alpha inhibitor
TNFPhase 1Healthy VolunteersJun 2027
Fondation Ophtalmologique Adolphe de Rothschildetanercept
TNF-alpha inhibitor
TNFPhase 1Alzheimer DiseaseJun 2028
Dong sheng ZhangrmhTNF-NC
Recombinant mutant human tumor necrosis factor
TNFPhase 1Malignant AscitesJun 2028
Kahr MedicalDSP107
SIRPα-4-1BBL bi-functional fusion protein; engages SIRPα on macrophages (CD172a) to block
SIRPA, TNFPhase 1Advanced Solid Tumor–

Conditions

Rheumatoid Arthritis (9) Crohn Disease (9) Ulcerative Colitis (5) Alcohol Use Disorder (3) Takayasu Arteritis (2) Melanoma Stage III (2) Locally Advanced Basal Cell Carcinoma (2) Malignant Ascites (2) Musculoskeletal Injury (2) Microscopic Colitis (2) Investigating the Importance of the Subjective Psychedelic Experience (2) Colitis (2)

Modalities

antibody (11), small molecule (8), mixed (7), protein or peptide (1)

Companies

University Hospital, Strasbourg, France (2) Chia Tai Tianqing Pharmaceutical Group (1) Fondation Ophtalmologique Adolphe de Rothschild (1) National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland (1) Wayne State University (1) Prestige Biopharma (1) Philogen (1) Dong sheng Zhang (1) Kahr Medical (1) Connecticut Children's Medical Center (1) Memorial Sloan Kettering Cancer Center (1) London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) Assistance Publique - Hôpitaux de Paris (1) Sir Run Run Shaw Hospital (1) University of Calgary (1) Odense University Hospital (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) University of Pennsylvania (1) David Ware Branch (1) Taizhou Mabtech Pharmaceutical (1)

Related targets

HTR2A (2) FKBP1A (2) SIRPA (1) IL6 (1) PDCD1LG1 (1) CNR1 (1) PLAT (1) IL12B (1) IL23A (1) ADRB2 (1) NR3C1 (1) PTGS2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.